Accordingly, BAY 11-7082 could be considered an effective inhibitor targeting NRAS, KRAS, and HRAS mutant cancer and serve as a promising candidate for more effective treatments tailored to all RAS-mutant cancers. Here, KRAS is linked to cancer.